Drugs / Venlafaxine Extended Release
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00766870 | Sep 2008 → Jan 2009 | major depressive disorder | H. Lundbeck A/S | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02497287 Background | Sep 2015 → Oct 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02422186 Background | Aug 2015 → Aug 2017 | major depressive disorder | Janssen Research & Development, LLC | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Venlafaxine extended release | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00766870 ↗ |
| Known as | Venlafaxine extended release (XR) | “In addition, each participant will be assigned to receive 1 of 4 oral antidepressant medications from 2 different classes of antidepressant treatments, a Selective Serotonin...” NCT02422186 ↗ |
| Route | Oral | “Per oral, once daily” NCT00766870 ↗ |